ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

ClinicalTrials.gov ID: NCT04569747

Public ClinicalTrials.gov record NCT04569747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Study identification

NCT ID
NCT04569747
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dana-Farber Cancer Institute
Other
Enrollment
393 participants

Conditions and interventions

Interventions

  • ADJUVANT ENDOCRINE THERAPY Drug
  • Pertuzumab+TRASTUZUMAB Combination Product

Drug · Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2021
Primary completion
Mar 22, 2026
Completion
Aug 31, 2030
Last update posted
Apr 1, 2026

2021 – 2030

United States locations

U.S. sites
32
U.S. states
13
U.S. cities
23
Facility City State ZIP Site status
Stamford Hospital Stamford Connecticut 06904
University of Miami- Sylvester Comprehensive Cancer Center Miami Florida 33136
Winship Cancer Institute at Emory University Hospital Midtown Atlanta Georgia 30308
Emory University - Winship Cancer Institute Atlanta Georgia 30322
Winship Cancer Institute at Emory Saint Joseph's Hospital Atlanta Georgia 30342
University of Chicago Medical Center Chicago Illinois 60637
Indiana University Health Schwarz Cancer Center Indianapolis Indiana 46032
Indiana University Health - Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202
Indiana University Sidney and Lois Eskenazi Hospital Indianapolis Indiana 46202
Eastern Maine Medical Center (Northern Light) Brewer Maine 04412
Dana Farber Cancer Institite Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Dana-Farber Brigham Cancer Center - Foxborough Foxborough Massachusetts 02035
Cape Cod Healthcare Center Hyannis Massachusetts 02601
Dana-Farber at Milford Milford Massachusetts 01757
Dana-Farber at South Shore Hospital Weymouth Massachusetts 02190
Dana-Farber Cancer Insitute at Londonderry Hospital Londonderry New Hampshire 03053
New York University Langone Hospital -Brooklyn Brooklyn New York 11220
New York University Langone Hospital - Long Island Mineola New York 11501
New York University Langone Health New York New York 10016
UNC Rex Hematology Oncology Associated - Cary Cary North Carolina 27518
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599
UNC Rex Hematology Oncology Associates of Garner Garner North Carolina 27529
UNC Rex Cancer Center Raleigh North Carolina 27607
UNC Rex Cancer Center at Wakefield Raleigh North Carolina 27614
The Christ Hospital Cincinnati Ohio 45219
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Greco-Hainsworth Centers for Research/Tennessee Oncology Nashville Tennessee 37203
SCRI Oncology Partners Nashville Tennessee 37203
Vanderbilt University Medical Center Nashville Tennessee 37203
Baylor College of Medicine Medical Center Houston Texas 77030
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04569747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2026 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04569747 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →